Thirty-one dyspeptic subjects (16 men, 15 women; 50.8 ¡À 16.7 years) were diagnosed as HP positive using histopathological evaluation. Eleven dyspeptic subjects (5 men, 6 women; 55.4 ¡À 9.3 years) were negative to HP (controls). Interleukin-6 level and vascular measurements (ankle brachial index and flow-mediated diameter percent change) were done twice: on entry and 3 months afterwards. HP-positive subjects were treated with the triple therapy.
Thirty-one HP-positive subjects (50.8 ¡À 16.7 years, 16 men, weight 79.6 ¡À 14.8 kg, height 1.70 ¡À 0.1 m, body mass index [BMI] 27.5 ¡À 4.4, waist circumference 97.6 ¡À 16.7 cm) were treated accordingly. There were 11 HP-negative subjects (controls) (55.4 ¡À 9.3 years, 5 men, weight 83.4 ¡À 16.8 kg, height 1.68 ¡À 0.1 m, BMI 29.6 ¡À 6.1, waist circumference 104.4 ¡À 13.7 cm). No difference in age (P = .27), weight (P = .51), height (P = .50), BMI (P = .30), or waist circumference (P = .20) was observed. HP-positive subjects had severe endothelial dysfunction (?.26 ¡À 8.4 % ) that improved after treatment (8.4 ¡À 9.0 % ) (P = .001). HP-negative subjects had endothelial dysfunction (1.9 ¡À 9.7 % ) that was not improved (5.6 ¡À 8.3 % ) (P = .41). Interleukin-6 levels in serum were not elevated in HP-positive subjects before or after HP eradication (8.4 ¡À 17.5 vs 13.5 ¡À 30.7 pg/mL; P = .45).
The novel finding of our study was that HP eradication can improve endothelial dysfunction.